Attenuation of chronic hypoxic pulmonary hypertension by simvastatin

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 3 54-3, 2003, Pages

  Girgis, Reda E ^a   Li, Dechun ^a   Zhan, Xinhua ^a   Garcia, Joe G N ^a   Tuder, Rubin M ^a   Hassoun, Paul M ^a   Johns, Roger A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibition; Nitric oxide; Polycythemia; Pulmonary vascular remodeling; Small G proteins

Indexed keywords

NITRIC OXIDE SYNTHASE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL WALL; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART WEIGHT; HEMATOCRIT; HYPOXIA; LUNG ALVEOLUS; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; NONHUMAN; OXYGEN BREATHING; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

EID: 0041859249     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01097.2002     Document Type: Article

References (47)

1. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, and Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32: 980-986, 2001.
2. Arai A, Kanda E, and Miura O. Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway. Oncogene 21: 2641-2651, 2002.
3. Archer S and Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress." Circulation 102: 2781-2791, 2000.
4. Blumberg FC, Wolf K, Arzt M, Lorenz C, Riegger GA, and Pfeifer M. Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs. J Appl Physiol 94: 446-452, 2002.
5. Bravo L, Herrera MD, Marhuenda E, and Perez-Guerrero C. Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats. Gen Pharmacol 30: 331-336, 1998.
6. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, and Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89:866-873, 2001.
7. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, and Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105: 691-696, 2002.
8. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of 02 sensing. J Biol Chem 275: 25130-25138, 2000.
9. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, and Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 276:46849-46855, 2001.
10. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, and Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150, 2001.
11. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
12. Everett AD, Le Cras TD, Xue C, and Johns RA. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol Lung Cell Mol Physiol 274: L1058-L1065, 1998.
13. Feron O, Dessy C, Desager JP, and Balligand JL. Hydroxy-methylglutaryl coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103: 113-118, 2001.
14. Fried R, Meyrick B, Rabinovitch M, and Reid L. Polycythemia and the acute hypoxic response in awake rats following chronic hypoxia. J Appl Physiol 55: 1167-1172, 1983.
15. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, and Bokelman DL. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl coenzyme A reductase inhibitors. Am J Med 87: 28S-38S, 1989.
16. Griscavage JM, Hobbs AJ, and Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234, 1995.
17. Hampl V and Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 80: 1337-1372, 2000.
18. Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, and Fukuchi Y. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol 277: L225-L232, 1999.
19. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, and White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105: 1446-1452, 2002.
20. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, and Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719, 1998.
21. Hernandez-Perera O, Perez-Sala D, Soria E, and Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87: 616-622, 2000.
22. Hislop A and Reid L. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br J Exp Pathol 57: 542-554, 1976.
23. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, and Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90: 1299-1306, 2001.
24. Janssens SP, Thompson BT, Spence CR, and Hales CA. Polycythemia and vascular remodeling in chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol 71: 2218-2223, 1991.
25. Jelkmann W and Hellwig-Burgel T. Biology of erythropoietin. Adv Exp Med Biol 502: 169-187, 2001.
26. Kalinowski L, Dobrucki LW, Brovkovych V, and Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105: 933-938, 2002.
27. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
28. Laufs U, Fata VL, and Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272: 31725-31729, 1997.
29. Laufs U, La FV, Plutzky J, and Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
30. Laufs U, Marra D, Node K, and Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kipl). J Biol Chem 274: 21926-21931, 1999.
31. Le Cras TD, Tyler RC, Horan MP, Morris KG, Tuder RM, McMurtry IF, Johns RA, and Abman SH. Effects of chronic hypoxia and altered hemodynamics on endothelial nitric oxide synthase expression in the adult rat lung. J Clin Invest 101: 795-801, 1998.
32. Li D, Zhou N, and Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol Lung Cell Mol Physiol 277: L841-L847, 1999.
33. McLaughlin VV, Shillington A, and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482, 2002.
34. Mukundan H, Resta TC, and Kanagy NL. 17β-Estradiol decreases hypoxic induction of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 283: R496-R504, 2002.
35. Murata T, Sato K, Hori M, Ozaki H, and Karaki H. Decreased eNOS activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 277: 44085-44092, 2002.
36. Naeye RL. Polycythemia and hypoxia. Individual effects on heart and pulmonary arteries. Am J Pathol 50: 1027-1033, 1967.
37. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, and Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166: 1403-1408, 2002.
38. Resta TC, Chicoine LG, Omdahl JL, and Walker BR. Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol Heart Circ Physiol 276: H699-H708, 1999.
39. Robertson TP, Dipp M, Ward JP, Aaronson PI, and Evans AM. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 131: 5-9, 2000.
40. Seeger H, Mueck AO, and Lippert TH. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Int J Clin Pharmacol Ther 38: 270-272, 2000.
41. Stark, WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, and Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 275: L55-L63, 1998.
42. Szczeklik A, Undas A, Musial J, Gajewski P, Swadzba J, and Jankowski M. Antithrombotic actions of statins. Med Sci Monit 7: 1381-1385, 2001.
43. Takai Y, Sasaki T, and Matozaki T. Small GTP-binding proteins. Physiol Rev 81: 153-208, 2001.
44. Takemoto M and Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
45. Touvay C, Vilain B, Carre C, Mencia-Huerta JM, and Braquet P. Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary hypertension. Int Arch Allergy Immunol 107: 272-274, 1995.
46. Weissmann N, Winterhalder S, Nollen M, Voswinckel R, Quanz K, Ghofrani HA, Schermuly RT, Seeger W, and Grimminger F. NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol 280: L638-L645, 2001.
47. Xu CB, Stenman E, and Edvinsson L. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol 64: 497-505, 2002.